Sleep aid taken by 2 million people 'significantly' impairs next-day function, world-first study finds
A world-first Australian clinical trial by Flinders University found that a 50 mg bedtime dose of quetiapine (Seroquel), often used off-label for insomnia, improved sleep and reduced obstructive sleep apnea breathing pauses by about 24% versus placebo in 15 participants, but impaired next-day performance. Researchers reported slower reaction times and worse driving-simulator lane control, with nearly twice as many crashes (55 vs 27). The study, published in the Annals of the American Thoracic So
Background
Quetiapine (Seroquel) is approved for schizophrenia but is commonly prescribed off-label for insomnia; the study tests whether a 50 mg bedtime dose affects next-morning function in people with obstructive sleep apnea.
Why it matters
A randomized, blinded sleep-lab trial finds modest overnight sleep/breathing benefits but measurable next-day impairment (reaction time and driving-simulator lane control), supporting a practical avoidance window of ~9.5 hours for safety-sensitive tasks.
Market relevance
This is a drug-safety evidence update that could affect off-label prescribing practices and safety labeling discussions, but the article does not identify a specific US-listed manufacturer as the subject.
Market effects
Highlights safety/regulatory scrutiny risk for off-label sedative use of quetiapine; may pressure prescriber behavior and payer policies for insomnia indications.
Primarily US prescribing context is cited, but trial is Australian; limited immediate regional market impact.
Could influence international sleep/respiratory-safety discussions around off-label antipsychotic prescribing.
Alternative perspectives
The trial is small (n=15) and uses a single low dose; real-world effects may vary by patient, tolerance, and co-medications.
The article focuses on next-day driving/sedation but does not quantify broader incidence rates, long-term outcomes, or how results translate to different dosing schedules and patient comorbidities.
Key entities
- drugQuetiapine
Atypical antipsychotic commonly used off-label as a sleep aid; study reports next-day alertness and driving impairment after 50 mg bedtime dosing.
- institutionFlinders University
Australian research team conducting the world-first clinical trial published in the Annals of the American Thoracic Society.
